RVTY250117C110000
- 9.00
- 0.000.00%
Revvity Newsroom
Revvity Announces FDA Clearance for First Automated Free Testosterone Test
Bernstein Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $130
Express News | Revvity Inc: Agreement Provides for a $1.5 Bln Committed Unsecured Revolving Credit Facility Available Through Jan 7, 2030
Express News | Revvity Inc: Entered Into Credit Agreement With Revvity and Revvity Health Sciences, Inc
Bernstein Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $145
Bernstein Remains a Buy on Revvity (RVTY)
Revvity (NYSE:RVTY) Investors Are Sitting on a Loss of 38% If They Invested Three Years Ago
Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $125
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Revvity Inc. Stock Rises Tuesday, Still Underperforms Market
Express News | Revvity Inc : Jefferies Cuts Target Price to $120 From $125
UBS Says 'Underweight the Names With High China Exposure'
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford Nanopore - ResearchAndMarkets.com
Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?
Citi Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $145
Revvity's Strategic Market Position and Anticipated Growth Drive Buy Rating
Revvity to Present at J.P. Morgan Healthcare Conference
BofA Securities Upgrades Revvity(RVTY.US) to Buy Rating, Announces Target Price $138
BofA Securities Upgrades Revvity to Buy From Neutral
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)